The plain version
Nothing on cannabless.org is medical advice. Nothing here is a clinical recommendation. Nothing here should influence whether you, your patient, or anyone you care for takes a medication, changes a dose, starts treatment, or stops treatment.
We are a B2B medical-cannabis exporter. Our content is written for procurement professionals at licensed importers, regulators, journalists, and clinical-research collaborators. It describes regulatory pathways, supply-chain standards, and operational practices. It is not patient-facing material.
If you are a patient
Please discuss any medical-cannabis question with a licensed prescriber in your country of residence. They are the only person qualified to assess your specific clinical situation, your medication interactions, your contraindications, and the appropriateness of cannabis or any cannabinoid medication for you.
Medical cannabis carries clinically significant side effects, including impaired cognition, sedation, anxiety in some patients, and interactions with other medications (notably warfarin, certain anti-epileptics, and CYP3A4-metabolised drugs). Patients with a personal or family history of psychotic disorders may be at elevated risk from THC-dominant cannabinoid medications. None of this is exhaustive — your prescriber will assess in detail.
If you are pregnant, breastfeeding, or trying to conceive: cannabinoids are generally contraindicated. Please raise this with your prescriber before any cannabis-based medication is considered.
If you are a prescriber
Our content describes regulatory and supply-chain context that may be useful when you prescribe imported medical-cannabis products. It does not substitute for your clinical training, your prescribing protocols, your local regulatory guidance, or the peer-reviewed clinical literature in your specialty.
Where we cite chemistry or pharmacology, the underlying primary literature is consulted before publication. Where we describe a regulatory pathway, the underlying regulator documents (TGA, BfArM, IMC, MOPH/ONCB, Health Canada, etc.) are the source of truth and should be consulted directly for any decision affecting a specific patient.
If you are a regulator or auditor
Our content references regulatory frameworks as we understand them at publication. Regulatory frameworks change. The authoritative source is always the regulator’s own published guidance. Where you find a discrepancy between our content and the regulator’s current guidance, the regulator’s guidance is correct and we will correct our page on notification.
Markets we do not serve
CannaBless supplies licensed medical importers in regulated markets only — primarily Australia (TGA SAS-B / Authorised Prescriber), Germany (BfArM / EU-GMP), Israel (IMC), and Switzerland. We do not supply recreational or adult-use markets, even where they are legal. We do not supply jurisdictions where regulated medical access for cannabis does not exist; such jurisdictions are geographically restricted at the edge (see /unavailable).
No emergency advice
If you are experiencing a medical emergency related to medication use of any kind, please contact your local emergency medical services immediately. This site does not provide and cannot substitute for emergency medical care.
Editorial integrity
Our editorial process and limits are documented at /editorial-standards. If you believe a passage on this site reads as patient-facing medical advice or otherwise mischaracterises a clinical or regulatory point, please write to contact@cannabless.org.
Last reviewed .